上方“瞪羚社”即刻关注并加入社群聚焦高成长公司，100000+投资菁英共同关注MNC都在寻找一柄利器，能击败“自免药王”度普利尤单抗（Dupilumab，以下简称“Dupi”）的全新迭代分子。Dupi在2024年销售额为135.57亿美元（同比增长17.2%），销售额仅次于K药和司美格鲁肽，2017年上市以来累积销售额约为496.72亿美元（截至2024年销售额），海外机构普遍预测其销售峰值将突破...
Source Link上方“瞪羚社”即刻关注并加入社群聚焦高成长公司，100000+投资菁英共同关注MNC都在寻找一柄利器，能击败“自免药王”度普利尤单抗（Dupilumab，以下简称“Dupi”）的全新迭代分子。Dupi在2024年销售额为135.57亿美元（同比增长17.2%），销售额仅次于K药和司美格鲁肽，2017年上市以来累积销售额约为496.72亿美元（截至2024年销售额），海外机构普遍预测其销售峰值将突破...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.